PuSH - Publikationsserver des Helmholtz Zentrums München

Fragkou, P.C.* ; De Angelis, G.* ; Menchinelli, G.* ; Can, F.* ; Garcia, F.* ; Morfin-Sherpa, F.* ; Dimopoulou, D.* ; Dimopoulou, K.* ; Zelli, S.* ; de Salazar, A.* ; Reiter, R.* ; Janocha, H.* ; Grossi, A.* ; Omony, J. ; Skevaki, C.*

Update of European Society of Clinical Microbiology and Infectious Diseases coronavirus disease 2019 guidelines: Diagnostic testing for severe acute respiratory syndrome coronavirus 2.

Clin. Microbiol. Infect. 29, 876-886 (2023)
Verlagsversion DOI PMC
Free by publisher
Open Access Green möglich sobald Postprint bei der ZB eingereicht worden ist.
SCOPE: Since the onset of COVID-19, several assays have been deployed for the diagnosis of SARS-CoV-2. The European Society of Clinical Microbiology and Infectious Diseases (ESCMID) published the first set of guidelines on SARS-CoV-2 in vitro diagnosis in February 2022. Because the COVID-19 landscape is rapidly evolving, the relevant ESCMID guidelines panel releases an update of the previously published recommendations on diagnostic testing for SARS-CoV-2. This update aims to delineate the best diagnostic approach for SARS-CoV-2 in different populations based on current evidence. METHODS: An ESCMID COVID-19 guidelines task force was established by the ESCMID Executive Committee. A small group was established, half appointed by the chair, and the remaining selected with an open call. The panel met virtually once a week. For all decisions, a simple majority vote was used. A list of clinical questions using the population, intervention, comparison, and outcome (PICO) format was developed at the beginning of the process. For each PICO, 2 panel members performed a literature search focusing on systematic reviews with a third panellist involved in case of inconsistent results. The panel reassessed the PICOs previously defined as priority in the first set of guidelines and decided to address 49 PICO questions, because 6 of them were discarded as outdated/non-clinically relevant. The 'Grading of Recommendations Assessment, Development and Evaluation (GRADE)-adoption, adaptation, and de novo development of recommendations (ADOLOPMENT)' evidence-to-decision framework was used to produce the guidelines. QUESTIONS ADDRESSED BY THE GUIDELINES AND RECOMMENDATIONS: After literature search, we updated 16 PICO questions; these PICOs address the use of antigen-based assays among symptomatic and asymptomatic patients with different ages, COVID-19 severity status or risk for severe COVID-19, time since the onset of symptoms/contact with an infectious case, and finally, types of biomaterials used.
Altmetric
Weitere Metriken?
[➜Einloggen]
Zusatzinfos bearbeiten [➜Einloggen]
Publikationstyp Artikel: Journalartikel
Dokumenttyp Wissenschaftlicher Artikel
Korrespondenzautor
Schlagwörter Covid-19 ; Diagnosis ; Guidelines ; Sars-cov-2 ; Testing; Rapid Antigen Test; Polymerase-chain-reaction; Sars-cov-2 Infection; Analytical Performances; Quicknavitm-covid19 Ag; Asymptomatic Patients; Covid-19; Accuracy; Utility; Immunoassay
ISSN (print) / ISBN 1198-743X
e-ISSN 1469-0691
Zeitschrift Clinical Microbiology and Infection
Quellenangaben Band: 29, Heft: 7, Seiten: 876-886 Artikelnummer: , Supplement: ,
Verlag Wiley
Verlagsort The Boulevard, Langford Lane, Kidlington, Oxford Ox5 1gb, Oxon, England
Nichtpatentliteratur Publikationen
Begutachtungsstatus Peer reviewed
Institut(e) Institute of Asthma and Allergy Prevention (IAP)
Förderungen Acciones de Intensificacion del personal investigador
Fundacion Progreso y Salud, Consejeria de Salud, Junta de Andalucia
Foundation for Pathobiochemistry and Molecular Diagnostics
Deutsche Forschungsgemeinschaft (DFG, German Research Foundation)
German Center for Lung Research (DZL) , University Hospital Giessen and Marburg (UKGM)
Universities of Giessen and Marburg Lung Center (UGMLC)